BPC-157 (Body Protection Compound 157)

BPC-157 is a 15-amino acid synthetic peptide said to be derived from a 'body protection compound' found in human gastric juice. The bulk of the research on BPC-157 — dozens of publications — comes from a single Croatian research group led by Sikiric, spanning three decades.^[1] Its structure is not found as a naturally-occurring peptide in humans; the compound is entirely synthetic.

BPC-157 is not FDA-approved for any indication. In late 2023, the FDA placed BPC-157 on Category 2 of the 503A bulks list — effectively restricting compounding pharmacies from producing it — and removed it from the approvable compounding list, citing lack of sufficient safety data.

BPC-157 emerged from research at the University of Zagreb led by Predrag Sikiric, who first reported a fragment of the larger BPC ("body protection compound") family of gastric juice proteins. The Sikiric group has since published more than a hundred preclinical papers exploring BPC-157 in tendon, ligament, gut, brain, and vascular models — a body of work substantial enough that the field has come to treat the molecule as the canonical example of a "general protector peptide."

Outside the originating lab, independent replication is more limited but growing, including in vitro work on tendon-derived stem cell proliferation and angiogenesis-related signaling. Wider human investigation has been slowed by regulatory uncertainty and by a fragmented research-grade marketplace, but interest in formal clinical evaluation continues.

The proposed mechanisms in rodent models are many, sometimes overlapping, and often described only in the originating group's papers:

• Upregulation of growth hormone receptor expression in tendon fibroblasts (supporting tendon healing hypothesis)
• Interaction with the nitric oxide pathway
• Angiogenic effects — promoting new blood vessel formation in injury sites
• Modulation of dopaminergic and serotonergic systems (claimed gut-brain axis effects)
• Protective effects against a wide range of experimentally-induced injuries

The breadth of claimed effects is itself a warning sign — peptides with coherent mechanistic stories typically act on a smaller, better-defined set of pathways.

Plasma pharmacokinetics in rats are characterized by rapid clearance, which is unusual for a peptide credited with lasting tissue effects. The mechanistic interpretation in the Sikiric literature is that BPC-157 acts locally on injured tissue and through indirect signaling pathways — angiogenesis, growth-factor receptor expression, nitric oxide modulation — rather than maintaining sustained systemic levels.

Multiple routes of administration have been studied in animal work, including subcutaneous, intraperitoneal, intragastric, and oral (in drinking water). Each has shown activity in at least some models. Comprehensive human pharmacokinetic data is not yet available in the published literature.

The peer-reviewed literature on BPC-157 is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).

This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.

In the preclinical literature, BPC-157 has been administered subcutaneously, intragastrically, intraperitoneally, and in drinking water in rats — all with reports of activity. User communities describe subcutaneous and oral routes; neither has been independently validated in controlled human trials.

This page describes routes used in research only. This is not a usage guide.

BPC-157 occupies a uniquely interesting position in modern peptide research. The animal-model literature is broad, internally consistent, and growing — particularly in tendon, ligament, and gastrointestinal mucosal models — and the user-reported experience base is large enough that thoughtful clinicians and researchers continue to take it seriously. At the same time, the controlled human evidence required to translate animal-model findings into clinical confidence is still developing.

For readers thinking about BPC-157, the substantive questions are about evidence quality, regulatory status, and where the field is heading. Independent human RCTs would dramatically clarify the picture. Until they appear, conclusions about clinical efficacy in humans necessarily rest on translation from animal data plus the cumulative weight of structured user reports — a combination that warrants careful reading rather than confident dismissal or confident endorsement.